Skip to content

Surgical Management of stable vitiligo.

A Comparative study between Autologous Mini punch grafting, Suction blister grafting and Non Cultured Epidermal cell suspension on resistant sites in stable vitiligo.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/07/014871
Enrollment
20
Registered
2018-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- HAVING STABLE VITILIGO ON RESISTANT SITES LIKE ACRAL AREAS AND BONY PROMINENCES. Health Condition 2: L80- Vitiligo

Interventions

Intervention1: AUTOLOGOUS MINI PUNCH GRAFTING, SUCTION BLISTER GRAFTING AND NON-CULTURED EPIDERMAL CELL SUSPENSION.: Compare extent of repigmentation after 12 weeks of procedure. Control Intervention

Sponsors

DEPARTMENT OF DERMATOLOGY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with clinical diagnosis of focal, segmental or generalized vitiligo. 2. Patients with lesions of size > 1.5cm x 1cm present on acral areas and bony prominences. 3. Vitiligo lesions has been stable for 1 year. 4. Disease not responding to medical treatment or there are residual patches (after medical therapy) of vitiligo which in turn are located on acral areas and bony prominences. 5. Maximum size of vitiligo patches to be selected for surgery will not be >100cm2.

Exclusion criteria

Exclusion criteria: 1) Age less than 18 years 2) Pregnancy and lactation 3) Patient with actively spreading vitiligo 4) History of Koebnerisation 5) History of hypertrophic scars or keloidal tendency 6) Bleeding disorders 7) Patients with unrealistic expectation

Design outcomes

Primary

MeasureTime frame
To assess the difference in extent of repigmentation by three different methods at 12 weeks of post treatment follow up in a given patient. Timepoint: Follow up will be done on Day 8, then at 4, 8 and 12 weeks.

Secondary

MeasureTime frame
1. Pattern of repigmentation attained post-procedure. 2. Color matching of repigmented area. 3. Patient satisfaction (patient global assessment) and quality of life assessement post procedure. 4. Adverse events if any. Timepoint: Follow up will be done on Day 8,then at 4,8 and 12 weeks.

Countries

India

Contacts

Public ContactM SENDHIL KUMARAN

DEPARTMENT OF DERMATOLOGY, POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH.

drsen_2000@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026